Lightner, Amy L.
Chan, Timothy
Article History
Received: 23 September 2020
Accepted: 9 December 2020
First Online: 7 January 2021
Ethics approval and consent to participate
: Not applicable given there is no human subject data or participants.This does not involve the participation of an ethics approval or institutional review board approval.There is no involvement of animals.
: Not appliable
: Dr. Lightner is a consultant for Takeda.Tim Chan: T.A.C. is a co-founder of Gritstone Oncology and holds equity. T.A.C. holds equity in NysnoBio. T.A.C. acknowledges grant funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has served as an advisor for Bristol-Myers, MedImmune, Squibb, Illumina, H3/Eisai, AstraZeneca, and An2H. T.A.C. holds ownership of intellectual property on using tumor mutation burden to predict immunotherapy response, with pending patent, which has been licensed to PGDx.